- Topics
- Regions
- Events
- Webcasts
- Resources
- CW Exclusives
- Membership
“For tracking litigation, enforcement, and regulatory developments, Compliance Week
should be your prime source.”- Chief Compliance Officer and VP of Legal Affairs, Arrow Electronics
Distilling compliance lessons from Novartis
Ethics and compliance officers in the pharmaceutical industry can learn a lot from the troubles of Novartis, which faced a firestorm of criticism from shareholders at its last annual meeting.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticleNovartis to pay $347M to resolve FCPA investigations
Novartis will pay nearly $347 million in combined criminal and civil penalty settlements with U.S. authorities to resolve all FCPA investigations into historical conduct by the company and its subsidiaries.
-
ArticleNovartis sets aside $700M in kickback case
Swiss pharmaceutical drug maker Novartis announced it has set aside $700 million for a potential settlement in a long-running lawsuit over allegations that the company paid hundreds of millions of dollars in kickbacks to doctors to induce them into prescribing drugs to patients to boost their sales.
-
Blog
Novartis strengthens executive committee further
Novartis this week announced changes to its senior leadership team to support the implementation of its strategic priorities. These changes include the appointment of Shannon Klinger in the elevated and expanded role of chief ethics, risk, and compliance officer, effective April 1.